This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adjei, A. A. Articles by Kaufmann, S. H. Search for Related Content PubMed PubMed Citation Articles by Adjei, A. A. Articles by Kaufmann, S. H.

A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity¹

Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905 [A. A. A., C. E., J. N. D., J. A. S., R. S. M., L. J. H., P. A. S., P. A., S. H. K.], and Schering-Plough Research Institute, Kenilworth, New Jersey 07033 [D. L. C., W. R. B., P. K.]

Farnesylprotein transferase (FT), an enzyme that catalyzes the first step in the posttranslational modification of ras and a number of other polypeptides, has emerged as an important target for the development of anticancer agents. SCH66336 is one of the first FT inhibitors to undergo clinical testing. We report a Phase I trial to assess the maximum tolerated dose, toxicities, and biological effectiveness of SCH66336 in inhibiting FT in vivo. Twenty patients with solid tumors received 92 courses of escalating SCH66336 doses given orally twice a day (b.i.d.) for 7 days out of every 3 weeks. Gastrointestinal toxicity (nausea, vomiting, and diarrhea) and fatigue were dose-limiting at 400 mg of SCH66336 b.i.d. Moderate reversible renal insufficiency, secondary to dehydration from gastrointestinal toxicity, was also seen. Inhibition of prelamin A farnesylation in buccal mucosa cells of patients treated with SCH66336 was demonstrated, confirming that SCH66336 inhibits protein farnesylation in vivo. One partial response was observed in a patient with previously treated metastatic non-small cell lung cancer, who remained on study for 14 months. This study not only establishes the dose for future testing on this schedule (350 mg b.i.d.) but also provides the first evidence of successful inhibition of FT in the clinical setting and the first hint of clinical activity for this class of agents.

This article has been cited by other articles:

				S. H. Oh, Q. Jin, E. S. Kim, F. R. Khuri, and H.-Y. Lee Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin-Mediated Increases in Survivin Expression Clin. Cancer Res., March 1, 2008; 14(5): 1581 - 1589. [Abstract] [Full Text] [PDF]

				M. Loprevite, M. Tiseo, M. Chiaramondia, M. Capelletti, C. Bozzetti, B. Bortesi, N. Naldi, R. Nizzoli, P. Dadati, A. Kunkl, et al. Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Non Small Cell Lung Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6518 - 6526. [Abstract] [Full Text] [PDF]

				T. Raz, V. Nardi, M. Azam, J. Cortes, and G. Q. Daley Farnesyl transferase inhibitor resistance probed by target mutagenesis Blood, September 15, 2007; 110(6): 2102 - 2109. [Abstract] [Full Text] [PDF]

				M. W. Kieran, R. J. Packer, A. Onar, S. M. Blaney, P. Phillips, I. F. Pollack, J. R. Geyer, S. Gururangan, A. Banerjee, S. Goldman, et al. Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study J. Clin. Oncol., July 20, 2007; 25(21): 3137 - 3143. [Abstract] [Full Text] [PDF]

				S.-Y. Sun, X. Liu, W. Zou, P. Yue, A. I. Marcus, and F. R. Khuri The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells J. Biol. Chem., June 29, 2007; 282(26): 18800 - 18809. [Abstract] [Full Text] [PDF]

				J. E. Lancet, I. Gojo, J. Gotlib, E. J. Feldman, J. Greer, J. L. Liesveld, L. M. Bruzek, L. Morris, Y. Park, A. A. Adjei, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia Blood, February 15, 2007; 109(4): 1387 - 1394. [Abstract] [Full Text] [PDF]

				C. X. Ma, P. Steen, K. M. Rowland, R. D. Niedringhaus, T. R. Fitch, J. W. Kugler, D. W. Hillman, E. A. Perez, J. N. Ingle, and A. A. Adjei A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study Ann. Onc., February 1, 2006; 17(2): 226 - 231. [Abstract] [Full Text] [PDF]

				A. D. Basso, P. Kirschmeier, and W. R. Bishop Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors J. Lipid Res., January 1, 2006; 47(1): 15 - 31. [Abstract] [Full Text] [PDF]

				S. Murthy, H. Tong, and R. J. Hohl Regulation of Fatty Acid Synthesis by Farnesyl Pyrophosphate J. Biol. Chem., December 23, 2005; 280(51): 41793 - 41804. [Abstract] [Full Text] [PDF]

				E. David, S.-Y. Sun, E. K. Waller, J. Chen, F. R. Khuri, and S. Lonial The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT Blood, December 15, 2005; 106(13): 4322 - 4329. [Abstract] [Full Text] [PDF]

				N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens Development of Farnesyl Transferase Inhibitors: A Review Oncologist, September 1, 2005; 10(8): 565 - 578. [Abstract] [Full Text] [PDF]

				L. M. Bruzek, J. N. Poynter, S. H. Kaufmann, and A. A. Adjei Characterization of a Human Carcinoma Cell Line Selected for Resistance to the Farnesyl Transferase Inhibitor 4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336) Mol. Pharmacol., August 1, 2005; 68(2): 477 - 486. [Abstract] [Full Text] [PDF]

				D. Ferguson, L. E. Rodriguez, J. P. Palma, M. Refici, K. Jarvis, J. O'Connor, G. M. Sullivan, D. Frost, K. Marsh, J. Bauch, et al. Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models Clin. Cancer Res., April 15, 2005; 11(8): 3045 - 3054. [Abstract] [Full Text] [PDF]

				J. Tabernero, F. Rojo, I. Marimon, M. Voi, J. Albanell, M. Guix, F. Vazquez, J. Carulla, M. Cooper, J. Andreu, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors J. Clin. Oncol., April 10, 2005; 23(11): 2521 - 2533. [Abstract] [Full Text] [PDF]

				D. CILLONI, F. MESSA, S. CARTURAN, F. ARRUGA, I. DEFILIPPI, E. MESSA, E. GOTTARDI, and G. SAGLIO Myelodysplastic Syndromes Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 400 - 408. [Abstract] [Full Text] [PDF]

				S. L. Moulder, J. J. Mahany, R. Lush, C. Rocha-Lima, M. Langevin, K. J. Ferrante, L. M. Bartkowski, S. M. Kajiji, D. A. Noe, S. Paillet, et al. A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors Clin. Cancer Res., November 1, 2004; 10(21): 7127 - 7135. [Abstract] [Full Text] [PDF]

				H.-J. Na, S.-J. Lee, Y.-C. Kang, Y.-L. Cho, W.-D. Nam, P. K. M. Kim, K.-S. Ha, H.-T. Chung, H. Lee, Y.-G. Kwon, et al. Inhibition of Farnesyltransferase Prevents Collagen-Induced Arthritis by Down-Regulation of Inflammatory Gene Expression through Suppression of p21ras-Dependent NF-{kappa}B Activation J. Immunol., July 15, 2004; 173(2): 1276 - 1283. [Abstract] [Full Text] [PDF]

				W. R. Parulekar and E. A. Eisenhauer Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997. [Abstract] [Full Text] [PDF]

				H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]

				Y. Takada, F. R. Khuri, and B. B. Aggarwal Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF-{kappa}B-regulated Gene Expression and Up-regulation of Apoptosis J. Biol. Chem., June 18, 2004; 279(25): 26287 - 26299. [Abstract] [Full Text] [PDF]

				F. R. Khuri, B. S. Glisson, E. S. Kim, P. Statkevich, P. F. Thall, M. L. Meyers, R. S. Herbst, R. F. Munden, C. Tendler, Y. Zhu, et al. Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors Clin. Cancer Res., May 1, 2004; 10(9): 2968 - 2976. [Abstract] [Full Text] [PDF]

				V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF]

				K.-H. Chun, H.-Y. Lee, K. Hassan, F. Khuri, W. K. Hong, and R. Lotan Implication of Protein Kinase B/Akt and Bcl-2/Bcl-XL Suppression by the Farnesyl Transferase Inhibitor SCH66336 in Apoptosis Induction in Squamous Carcinoma Cells Cancer Res., August 15, 2003; 63(16): 4796 - 4800. [Abstract] [Full Text] [PDF]

				J. A. Shabbits, Y. Hu, and L. D. Mayer Tumor Chemosensitization Strategies Based on Apoptosis Manipulations Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813. [Full Text] [PDF]

				S. R.D. Johnston, T. Hickish, P. Ellis, S. Houston, L. Kelland, M. Dowsett, J. Salter, B. Michiels, J. J. Perez-Ruixo, P. Palmer, et al. Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer J. Clin. Oncol., July 1, 2003; 21(13): 2492 - 2499. [Abstract] [Full Text] [PDF]

				A. A. Adjei, G. A. Croghan, C. Erlichman, R. S. Marks, J. M. Reid, J. A. Sloan, H. C. Pitot, S. R. Alberts, R. M. Goldberg, L. J. Hanson, et al. A Phase I Trial of the Farnesyl Protein Transferase Inhibitor R115777 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2520 - 2526. [Abstract] [Full Text] [PDF]

				A. A. Adjei, A. Mauer, L. Bruzek, R. S. Marks, S. Hillman, S. Geyer, L. J. Hanson, J. J. Wright, C. Erlichman, S. H. Kaufmann, et al. Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2003; 21(9): 1760 - 1766. [Abstract] [Full Text] [PDF]

				A. Nakajima, T. Tauchi, M. Sumi, W. R. Bishop, and K. Ohyashiki Efficacy of SCH66336, a Farnesyl Transferase Inhibitor, in Conjunction with Imatinib against BCR-ABL-positive Cells Mol. Cancer Ther., March 1, 2003; 2(3): 219 - 224. [Abstract] [Full Text] [PDF]

				F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF]

				F. G. El Kamar, M. L. Grossbard, and P. S. Kozuch Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care Oncologist, February 1, 2003; 8(1): 18 - 34. [Abstract] [Full Text] [PDF]

				S. R. D. Johnston, J. Head, S. Pancholi, S. Detre, L.-A. Martin, I. E. Smith, and M. Dowsett Integration of Signal Transduction Inhibitors with Endocrine Therapy: An Approach to Overcoming Hormone Resistance in Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 524S - 532S. [Abstract] [Full Text] [PDF]

				R. R. Hoover, F.-X. Mahon, J. V. Melo, and G. Q. Daley Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336 Blood, July 18, 2002; 100(3): 1068 - 1071. [Abstract] [Full Text] [PDF]

				G. K. Dy and A. A. Adjei Novel Targets for Lung Cancer Therapy: Part I J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894. [Abstract] [Full Text] [PDF]

				M. Crul, G. J. de Klerk, M. Swart, L. J. van't Veer, D. de Jong, L. Boerrigter, P. A. Palmer, C. J. Bol, H. Tan, G. C. de Gast, et al. Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer J. Clin. Oncol., June 1, 2002; 20(11): 2726 - 2735. [Abstract] [Full Text] [PDF]

				C. D. Britten, E. K. Rowinsky, S. Soignet, A. Patnaik, S.-L. Yao, P. Deutsch, Y. Lee, R. B. Lobell, K. E. Mazina, H. McCreery, et al. A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies Clin. Cancer Res., December 1, 2001; 7(12): 3894 - 3903. [Abstract] [Full Text] [PDF]

				L. R. Kelland, V. Smith, M. Valenti, L. Patterson, P. A. Clarke, S. Detre, D. End, A. J. Howes, M. Dowsett, P. Workman, et al. Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer Clin. Cancer Res., November 1, 2001; 7(11): 3544 - 3550. [Abstract] [Full Text] [PDF]

				S. Talapatra and C. B. Thompson Growth Factor Signaling in Cell Survival: Implications for Cancer Treatment J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 873 - 878. [Abstract] [Full Text]

				C. Ottoboni, A. Crippa, C. Falugi, and P. Russo Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations Mutagenesis, September 1, 2001; 16(5): 423 - 430. [Abstract] [Full Text] [PDF]

				M. M. Feldkamp, N. Lau, L. Roncari, and A. Guha Isotype-specific Ras{middle dot}GTP-Levels Predict the Efficacy of Farnesyl Transferase Inhibitors against Human Astrocytomas Regardless of Ras Mutational Status Cancer Res., June 1, 2001; 61(11): 4425 - 4431. [Abstract] [Full Text] [PDF]

				S. Pervin, R. Singh, C.-L. Gau, H. Edamatsu, F. Tamanoi, and G. Chaudhuri Potentiation of Nitric Oxide-induced Apoptosis of MDA-MB-468 Cells by Farnesyltransferase Inhibitor: Implications in Breast Cancer Cancer Res., June 1, 2001; 61(12): 4701 - 4706. [Abstract] [Full Text] [PDF]

				J. E. Karp, J. E. Lancet, S. H. Kaufmann, D. W. End, J. J. Wright, K. Bol, I. Horak, M. L. Tidwell, J. Liesveld, T. J. Kottke, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Blood, June 1, 2001; 97(11): 3361 - 3369. [Abstract] [Full Text] [PDF]

				A. W. Tolcher Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel Oncologist, June 1, 2001; 6(2008): 40 - 44. [Abstract] [Full Text] [PDF]

				A. A. Adjei, J. N. Davis, L. M. Bruzek, C. Erlichman, and S. H. Kaufmann Synergy of the Protein Farnesyltransferase Inhibitor SCH66336 and Cisplatin in Human Cancer Cell Lines Clin. Cancer Res., May 1, 2001; 7(5): 1438 - 1445. [Abstract] [Full Text]

				M. A. Morgan, O. Dolp, and C. W. M. Reuter Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling Blood, March 15, 2001; 97(6): 1823 - 1834. [Abstract] [Full Text] [PDF]

				A. Reichert, N. Heisterkamp, G. Q. Daley, and J. Groffen Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336 Blood, March 1, 2001; 97(5): 1399 - 1403. [Abstract] [Full Text] [PDF]

				D. G. Peters, R. R. Hoover, M. J. Gerlach, E. Y. Koh, H. Zhang, K. Choe, P. Kirschmeier, W. R. Bishop, and G. Q. Daley Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia Blood, March 1, 2001; 97(5): 1404 - 1412. [Abstract] [Full Text] [PDF]

				F. A.L.M. Eskens, A. Awada, D. L. Cutler, M. J.A. de Jonge, G. P.M. Luyten, M. N. Faber, P. Statkevich, A. Sparreboom, J. Verweij, A.-R. Hanauske, et al. Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors J. Clin. Oncol., February 15, 2001; 19(4): 1167 - 1175. [Abstract] [Full Text] [PDF]

				B. R. Korf Malignancy in Neurofibromatosis Type 1 Oncologist, December 1, 2000; 5(6): 477 - 485. [Abstract] [Full Text]

				H. R. Ashar, L. James, K. Gray, D. Carr, S. Black, L. Armstrong, W. R. Bishop, and P. Kirschmeier Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules J. Biol. Chem., September 22, 2000; 275(39): 30451 - 30457. [Abstract] [Full Text] [PDF]